Appetite suppressants in pregnancy
Language English Country Sweden Media print
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
23353864
PII: NEL330912A27
Knihovny.cz E-resources
- MeSH
- Appetite Depressants adverse effects therapeutic use MeSH
- Cyclobutanes adverse effects therapeutic use MeSH
- Databases, Factual statistics & numerical data MeSH
- Phentermine adverse effects therapeutic use MeSH
- Pregnancy Complications drug therapy epidemiology MeSH
- Drug Prescriptions statistics & numerical data MeSH
- Humans MeSH
- Abnormalities, Multiple epidemiology MeSH
- Obesity drug therapy epidemiology MeSH
- Prevalence MeSH
- Prospective Studies MeSH
- Pregnancy Trimester, First MeSH
- Risk Factors MeSH
- Abortion, Spontaneous epidemiology MeSH
- Pregnancy MeSH
- Check Tag
- Humans MeSH
- Pregnancy MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Geographicals
- Czech Republic epidemiology MeSH
- Names of Substances
- Appetite Depressants MeSH
- Cyclobutanes MeSH
- Phentermine MeSH
- sibutramine MeSH Browser
OBJECTIVES: Both, obesity as well as anorexia may be associated with infertility and other complications of pregnancy. Weight loss during pregnancy is therefore considered a risk factor. Weight loss and appetite suppressant are contraindicated during pregnancy, but the unintended exposure is probably not associated with higher risk. Our work was focused on trends in the appetite suppressants use in the Czech Republic and their embryotoxicity. METHODS: The pregnancies exposed to various appetite suppressants were followed prospectively in the years 1997-2012. The study group was compared to the comparison group which enrolled pregnant women exposed to non-teratogenic drugs. Drugs used as appetite suppressants were sibutramine and phentermine. RESULTS: Number of calls for this type of exposure was rare till 2005. Their number started to increase until 2009. Later, number of calls decreased because both drugs were withdrawn from the market. This finding reflects increasing tendency for the weight control in the group of fertile women in the Czech Republic. In our study, we did not reveal differences in pregnancy outcomes between study and comparison groups. CONCLUSIONS: However, we should be aware of the increasing food supplements exposure, that could be used as alternative to the appetite suppressants. Their potential risk results from the limited or completely absent control of their origin. Some of them have probably only placebo effect, but some of them could represent the risk.